“The prognosis of breast cancer in both men and women changes every day with each new knowledge we gain. In Italy we will have 55 thousand cases of breast cancer in 2022 with an age that is getting lower and lower. It is essential to intervene promptly. I would like to appeal to women: undergo screening, self-examination, even before the age of 50 because it is important to make an early diagnosis. Even the most aggressive tumors if caught early have a better prognosis ”. Thus Saviero Cinieri, president of Aiom (Italian Association of Medical Oncology), speech this morning at the press conference for the presentation of “Cancer: The new frontiers of treatments in oncology and hematology”, a scientific event organized at the La Nuvola Congress Center in Rome by AstraZeneca . “The knowledge has also led us to the fact that we target the Brca1 and 2 mutations – explains Cinieri -. Thanks to the anti-Parp molecules in these cases we are able as an adjuvant to manage the early phase of patients. We did it with breast, prostate and pancreatic cancer “. In the presence of” mutation, so-called agnostic drugs can also be used – underlines Cinieri – we do not start from the affected organ (lungs, colon, breast) but we need to look for the mutation that can be present anywhere. This is one of the many revolutions that will lead us to better manage our patients. “And in view of the next Aiom National Congress, scheduled for 1-2 and 3 October, Cinieri anticipates that” he will call ‘Oncology and complexity: the new challenges for oncologists’. In fact, oncologists today must be prepared to know all the molecular alterations that imply the growth of neoplastic cells and molecules active against the single mutation. It is not simple but we can no longer work alone, we have to work in tables that are defined as molecular tumor boards because we, surgeons and radiotherapists, can all together define the right disease and right therapy ”, he concludes.
Welcome! Log into your account
Recover your password
A password will be e-mailed to you.